Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries by Holmer, Magnus et al.
2082  |   wileyonlinelibrary.com/journal/liv Liver International. 2018;38:2082–2090.© 2018 John Wiley & Sons A/S. 
Published by John Wiley & Sons Ltd
 
Received: 15 February 2018  |  Accepted: 23 March 2018
DOI: 10.1111/liv.13751
N A F L D / N A S H
Nonalcoholic fatty liver disease is an increasing indication for 
liver transplantation in the Nordic countries
Magnus Holmer1,2  | Espen Melum3,4,5 | Helena Isoniemi6 | Bo-Göran Ericzon7 |  
Maria Castedal8 | Arno Nordin6 | Nicolai Aagaard Schultz9 | Allan Rasmussen9 |  
Pål-Dag Line10,11 | Per Stål1,2 | William Bennet8 | Hannes Hagström1,2
1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
2Division of Hepatology, Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden
3Division of Surgery, Inflammatory Diseases and Transplantation, Section for Gastroenterology, Department of Transplantation Medicine, Oslo University 
Hospital Rikshospitalet, Oslo, Norway
4Division of Surgery, Inflammatory Diseases and Transplantation, Department of Transplantation Medicine, Norwegian PSC Research Center, Oslo University 
Hospital Rikshospitalet, Oslo, Norway
5Division of Surgery, Inflammatory Diseases and Transplantation, Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway
6Department of Transplantation and Liver Surgery, University Hospital, Helsinki, Finland
7Division of Transplantation Surgery, Karolinska Institutet, CLINTEC, Stockholm, Sweden
8Transplant Institute, Sahlgrenska University Hospital, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
9Department of Surgical Gastroenterology and Liver Transplantation, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
10Division of Surgery, Inflammation Medicine and Transplantation, Section for Transplantation surgery, Department of Transplantation Medicine, Oslo 
University Hospital Rikshospitalet, Oslo, Norway
11Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Abbreviations: ALD, alcoholic liver disease; BMI, body mass index; CI, confidence interval; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; 
INR, international normalized ratio; LTX, liver transplantation; MELD, model for end-stage liver disease; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; 
NLTR, the Nordic liver transplant registry.
Correspondence
Hannes Hagström, Unit of Hepatology, 
Centre of Digestive Diseases, Karolinska 
University Hospital, Stockholm, Sweden.
Email: Hannes.hagstrom@ki.se
Funding information
HH was supported by grants from the 
Swedish Royal Academy of Sciences and the 
Swedish Gastroenterology Fund.
Handling Editor: Luca Valenti
Abstract
Background & Aims: Nonalcoholic fatty liver disease(NAFLD) is the second most 
common cause of liver transplantation in the US. Data on NAFLD as a liver transplan-
tation indication from countries with lower prevalences of obesity are lacking. We 
studied the temporal trends of NAFLD as an indication for liver transplantation in the 
Nordic countries, and compared outcomes for patients with NAFLD to patients with 
other indications for liver transplantation.
Method: Population- based cohort study using data from the Nordic Liver Transplant 
Registry on adults listed for liver transplantation between 1994 and 2015. NAFLD as 
the underlying indication for liver transplantation was defined as a listing diagnosis of 
NAFLD/nonalcoholic steatohepatitis, or cryptogenic cirrhosis with a body mass index 
≥25 kg/m2 and absence of other liver diseases. Waiting time for liver transplantation, 
mortality and withdrawal from the transplant waiting list were registered. Survival 
after liver transplantation was calculated using multivariable Cox regression, ad-
justed for age, sex, body mass index and model for end- stage liver disease.
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1  | INTRODUC TION
Nonalcoholic fatty liver disease (NAFLD) has become the most 
common liver disease globally.1,2 NAFLD is closely associated with 
obesity, diabetes type 2 and the metabolic syndrome.3 Previously, 
NAFLD has been underdiagnosed, and it is now approximated that 
50% of patients previously diagnosed as cryptogenic cirrhosis did 
in fact have NAFLD.4,5 Most NAFLD patients do not develop end- 
stage liver disease, but approximately 20% will develop nonalcoholic 
steatohepatitis (NASH), of which 20%- 40% will develop progressive 
liver fibrosis and of these, 10%- 20% progress further to cirrhosis.6,7 
Patients suffering from cirrhosis can deteriorate and develop de-
compensated cirrhosis, and are at an increased risk of developing 
hepatocellular carcinoma (HCC).8 Altogether the liver- specific mor-
tality for NAFLD patients is approximately 6%.5,9-11 For patients suf-
fering from decompensated cirrhosis or HCC, liver transplantation 
(LTX) is the most beneficial and often the only curative treatment 
option.12,13
Recent studies from the US show that NASH as an indication for 
LTX has increased by 170% between 2004 and 2013, making NASH 
the second most common cause after hepatitis C cirrhosis for need 
of LTX among adults in the US.14 Taking into account the effects of 
new effective treatments for chronic hepatitis C infection (HCV), a 
decrease in the number of HCV patients listed for LTX is projected.15 
The US data on NAFLD and LTX suggest that NASH will surpass HCV 
as the number one indication for LTX in the US in the near future.
Reports from the Centers for Disease Control and Prevention 
show that the prevalence of obesity (defined as a body mass index 
[BMI] ≥30 kg/m2) in the US has increased from 30.5% to 37.7% from 
1999 to 2014.16 Data on NAFLD as an indication for LTX from coun-
tries with lower prevalences of obesity are lacking. Although obe-
sity has increased notably in the Nordic countries, the prevalence 
is low compared to the US, ranging between 13.4% and 19.0%.17-20 
The spectrum of other liver diseases in the Nordic countries is also 
different compared to the US. Autoimmune liver diseases have been 
the most common indications for LTX since it was introduced as a 
treatment modality in the Nordic countries in the early 1980s.21
In addition to liver disease, NAFLD patients commonly have 
other comorbidities related to obesity such as diabetes type 2, hy-
pertension and cardiovascular disease.5,10 This puts NAFLD patients 
at a higher risk for complications following LTX.22,23 BMI has been 
shown to be an independent risk factor for post- operative mortality 
after LTX and previous studies have demonstrated that even though 
NAFLD patients have a comparable survival following LTX, they 
have a higher risk of cardiovascular complications and sepsis- related 
mortality.24 Also, NAFLD patients have an increased risk of recurring 
NAFLD and graft fibrosis post- LTX.25,26
1.1 | Aim
The aim of this study was to investigate if NAFLD is increasing as an 
indication for LTX in the Nordic countries compared to other liver 
diseases. We also aimed to determine if NAFLD patients have higher 
mortality after LTX compared to other indications.
Results: A total of 4609 patients listed for liver transplantation were included. NAFLD 
as the underlying indication for liver transplantation increased from 2.0% in 1994- 
1995 to 6.2% in 2011- 2015 (P = .01) and was the second most rapidly increasing indi-
cation. NAFLD patients had higher age, model for end- stage liver disease and body 
mass index when listed for liver transplantation, but overall survival after liver trans-
plantation was comparable to non- - NAFLD patients (aHR 1.03, 95% CI 0.70- 1.53 
P = .87).
Conclusion: NAFLD is an increasing indication for liver transplantation in the Nordic 
countries. Despite more advanced liver disease, NAFLD patients have a comparable 
survival to other patients listed for liver transplantation.
K E Y W O R D S
Liver cirrhosis, NASH, NLTR, obesity
Key points
• In the Nordic countries, nonalcoholic fatty liver disease 
(NAFLD) was the second most rapidly increasing indica-
tion for liver transplantation between 1994 and 2015.
• During the study period, the relative increase of NAFLD 
as an indication for liver transplantation was 153%.
• This trend was paralleled by an increased prevalence of 
obesity in the Nordic countries and in patients listed for 
liver transplantation.
• Mortality for NAFLD patients after liver transplantation 
was comparable to that of non-NAFLD patients.
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2  | MATERIAL S AND METHODS
2.1 | Study population and data collection
We used data from the Nordic Liver Transplant Registry (NLTR). The 
NLTR contains data from all transplantation centres in Denmark, 
Sweden, Norway and Finland since 1982, with data on BMI avail-
able since 1994. Cases listed for LTX between 1982 and 1993 were 
therefore excluded (N = 825). Between 1994 and 2015, 5995 pa-
tients were listed for LTX. From this cohort we excluded patients 
younger than 18 years (N = 801), cases where the indication for LTX 
was defined as highly urgent (these most likely did not represent 
typical NAFLD) (N = 438) and cases where data on height or weight 
were missing (N = 147). In total, 4 609 patients were included in the 
study (Figure 1).
Diagnoses in NLTR are coded by a specific classification system 
comprised by more than 90 different diagnostic codes. Data on se-
rologic markers for hepatitis B and C (HBV/HCV) are also available. 
We defined 6 specific groups based on these data. The congregated 
groups of diseases included: (i) NAFLD, (ii) autoimmune liver dis-
ease, (iii) alcoholic liver disease (ALD), (iv) chronic viral hepatitis, (v) 
HCC and (vi) other liver diseases. For a detailed description of these 
groups, see the Table S1.
We used 2 different approaches to define patients as NAFLD cases. 
Firstly, patients with specific coding for NAFLD/NASH were defined 
as NAFLD cases. Secondly, patients who were registered as cirrhosis 
of unknown cause or as cryptogenic cirrhosis, with a BMI ≥25 kg/m2 
at the time of listing for LTX and with no coding for any other liver 
disease were also defined as NAFLD cases. This method for defining 
NAFLD retrospectively is similar to that used by other authors.14,27,28 
Except for data on height and weight, no data on the presence of type 
2 diabetes or other traits of the metabolic syndrome was available in 
the NLTR.
The definition of chronic viral hepatitis was based on either a 
specific code or positive serologic markers for HBV or HCV. In the 
classification, HBV or HCV positivity was overriding the coexistence 
of alcoholic liver disease and autoimmune liver disease. For patients 
registered as HCC, there was limited data in the NLTR accounting for 
any underlying liver disease. Patients that did not fit into any of the 
categories described above were classified as other liver disease (Table 
S1).
To analyse temporal trends, the study population was stratified 
into 5 time periods based on the year of listing for LTX: 1994- 1995, 
1996- 2000, 2001- 2005, 2006- 2010 and 2011- 2015. Temporal 
trends for BMI for all cases included in the study were calculated. 
Additionally, temporal trends for BMI for cases classified as HCC 
were calculated separately.
Data on bilirubin, INR and creatinine levels at time of listing 
were used to calculate Model for End- Stage Liver Disease scores 
(MELD).29 The NLTR also contains data on history of ascites, defined 
as if the patient had ascites at any time before listing for LTX.
2.2 | Ethical considerations
The study was approved by the Regional ethical committee at 
Karolinska Institutet, Stockholm, Sweden. Dnr 2015/1011- 31/2.
2.3 | Statistical analysis
Continuous data is presented as medians and categorical data as 
percentages. Differences between patients with NAFLD and other 
indications for LTX were calculated using the Chi2 test for categorical 
parameters, and the Mann- Whitney U- test for continuous param-
eters. Changes in median BMI during the study periods were calcu-
lated using the Kruskal- Wallis test. Temporal trends were estimated 
as the percentage of the number of LTXs during each of the 5 time 
periods for each of the 6 diagnostic groups, using a non- parametric 
test for trend.30 The relative increase for each diagnostic group 
was calculated as the increase in per cent of the absolute number 
of cases from the second time period (1996- 2000) to the last time 
period (2011- 2015). The first time period (1994- 1995) was excluded 
from this calculation because of a small number of cases (N = 198).
Mortality after LTX was estimated comparing NAFLD patients 
to all non- NAFLD patients using multivariable Cox regression in 2 
separate models. In the first model, we adjusted for sex, age at list-
ing for LTX and BMI. In the second model, we further adjusted for 
MELD score. The Kaplan- Meier method was used to calculate sur-
vival curves.
F IGURE  1 Flow chart of study design 
and patient inclusion. Abbreviation: 
ALD, Alcoholic liver disease; HCC, 
Hepatocellular carcinoma; NAFLD, 
nonalcoholic liver disease; NLTR, Nordic 
Liver Transplant Registry
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In sensitivity analyses, we first defined NAFLD as in the main 
analysis but using a BMI cut- off of 30 kg/m2. Secondly, because of 
risk of recurrence of HCC or viral hepatitis after LTX, which could 
have negative effect on long- term survival, we estimated survival in 
NAFLD compared to other liver diseases but excluding cases with 
HCC or viral hepatitis. All analyses were performed in stata v 13.0 
(statacorp, College Station, Tx, USA).
3  | RESULTS
3.1 | Cohort characteristics
Of the included 4609 patients, 255 were identified as NAFLD 
cases. Demographical and clinical characteristics of patients at 
the time for listing for LTX are presented in Table 1. Forty- four 
NAFLD patients were identified by specific coding for NAFLD/
NASH and 211 patients met the criteria of having cryptogenic cir-
rhosis in combination with a BMI ≥25 kg/m2 and no other liver dis-
ease. Patients with NAFLD were older compared to other patients 
(57.9 vs 52.8 years, P < .001), had higher BMI (28.4 vs 24.3 kg/m2, 
P < .001) and higher MELD scores (16.8 vs 13.5, P < .001) at the 
time of listing for LTX. Complete data for calculating MELD was 
available for 2533 patients (55%). The gender distribution among 
NAFLD patients was comparable to non- NAFLD patients (63.1% 
vs 61.2% men, P = .53). Of the total study population, 52.2% had 
a history of ascites at the time of listing for LTX. The proportion 
of NAFLD patients with a history of ascites was significantly lower 
compared to patients with ALD and viral liver disease grouped to-
gether (70.1% vs 77.5%, P = .03).
The median BMI of the study population increased signifi-
cantly during the study period from 22.9 kg/m2 in the first period 
to 25.2 kg/m2 in the last period (P < .001). The prevalence of over-
weight (BMI 25- 30 kg/m2) and obesity (BMI ≥30 kg/m2) increased 
from 20.2% and 4.0%, respectively in the first period to 35.0% and 
17.2% in the last period (both P < .001) (Figure 2). The median BMI 
for HCC patients increased from 22.6 kg/m2 in the first period to 
27.5 kg/m2 in the last period (P < .001).
3.2 | Indications for liver transplantation
Of the total population, the proportion of patients who were listed 
for LTX owing to NAFLD increase from 2.0% in the first period 
(1994- 1995) to 6.2% in the last period (2011- 2015) (P .01). HCC was 
the diagnosis with the highest relative increase, from 3.5% of all 
cases in the first period to 19.7% in the last period (P < .001). Data 
Complete data (n) NAFLD (n = 255)
Non- NAFLD 
(n = 4354) P- value
Age, y, median 
(IQR)
4609 57.9 (50.7- 63.0) 52.8 (43.4- 59.6) <.001
Male, n (%) 4609 161 (63.1) 2,664 (61.2) .53
BMI kg/m2, 
median (IQR)
4609 28.4 (26.7- 31.2) 24.3 (21.9- 27.5) <.001
Creatinine, 
μmol/L, 
median (IQR)
3706 83 (68- 113) 73 (60- 92) <.001
INR, median 
(IQR)
2540 1.5 (1.3- 1.9) 1.3 (1.1- 1.6) <.001
Bilirubin, 
μmol/L, 
median (IQR)
3701 46 (25- 97) 41 (19- 97) .14
MELD, median 
(IQR)
2533 16.8 (12.6- 21.5) 13.5 (9.4- 18.1) <.001
BMI, Body Mass Index; INR, International Normalized Ratio; MELD, Model for End- stage Liver 
Disease.
Characteristics of patients listed for liver transplantation in the Nordic countries 1994- 2015. 
Paediatric patients, highly urgent cases and cases with incomplete data on BMI excluded.
TABLE  1 Characteristics of study 
population
F IGURE  2 Temporal trend on distribution between normal 
weight (BMI <25 kg/m2), over weight (BMI 25- 30 kg/m2) and 
obesity (BMI ≥30 kg/m2) in the total study population between 
1994 and 1995 and 2011 and2015. Abbreviations: BMI, body mass 
index
m2 m2 m2
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on temporal trends in LTX indications and BMI are presented in 
Table 2. Temporal trends for NAFLD compared to other chronic liver 
diseases (HCV, ALD and autoimmune liver disease) are presented 
graphically in Figure 3.
During the study period, all transplant indications increased 
in absolute numbers. Between 1996 and 2000, 36 patients were 
transplanted because of NAFLD. This number increased to 91 pa-
tients between 2011 and 2015, with an increase of 153%. NAFLD 
showed the second highest relative increment rate after HCC, that 
increased by 519% between the second and the last time period, 
from 47 to 291 cases. The relative increase for other groups of 
diagnoses were: 33% for other liver diseases, 53% for chronic viral 
hepatitis, 79% for autoimmune liver disease and 101% for ALD.
3.3 | Outcomes after listing for liver transplantation
There were no significant differences in waiting time or 
mortality while on the waiting list for LTX, or any increased 
risk of withdrawal from waiting list for NAFLD patients 
compared to patients being listed for LTX for other causes 
(Table 3).
3.4 | Outcomes after liver transplantation
Mortality after LTX for NAFLD patients was comparable to that of 
non- NAFLD patients, with a similar post- operative 90- day mortal-
ity in both unadjusted analysis (HR 1.36 95% CI 0.71- 2.59, P = .35) 
and when adjusted for age, sex, BMI and MELD (aHR 2.20 95% CI 
0.88- 5.51, P = .09). After both 1 year (aHR 1.39 95% CI 0.73- 2.62, 
TABLE  2  (a) Temporal trends in BMI at listing on waiting list for LTX. Changes in median BMI calculated using the Kruskal- Wallis test. 
P- value for significance of temporal trends between 1994 and 1995 to 2011 and 2015. (b) Temporal trends in indications for LTX in the 
Nordic countries between 1994 and 2015. Data is presented as absolute numbers of patients and percentages per each time period. Data on 
the changes in each indication for LTX was analysed using a test for trend. P- value for significance of temporal trends between 1994 and 
1995 to 2011 and 2015
(a)
Transplantation period
P1994- 1995 1996- 2000 2001- 2005 2006- 2010 2011- 2015
BMI category
BMI <25 kg/m2, % 75.8 62.9 53.9 51.5 47.8
BMI 25- 30 kg/m2, 
%
20.2 27.9 32.3 33 35
BMI >30 kg/m2, % 4.0 9.2 13.8 15.5 17.2
BMI, median (IQR) 22.9 (21.0- 24.9) 23.9 (21.4- 26.7) 24.6 (22.0- 27.7) 24.8 (22.1- 28.1) 25.2 (22.5- 28.4) <.001
(b)
1994- 1995 
n (%)
1996- 2000 
n (%)
2001- 2005 
n (%)
2006- 2010 
n (%)
2011- 2015 
n (%) P
Autoimmune liver 
disease
81 (40.9) 254 (34.0) 306 (33.4) 407 (32.0) 455 (30.8) .007
Alcoholic liver 
disease
27 (13.6) 100 (13.4) 143 (15.6) 158 (12.4) 201 (13.6) .57
Chronic viral 
hepatitis
26 (13.1) 136 (18.2) 164 (17.9) 226 (17.8) 208 (14.1) .002
Other liver disease 55 (27.7) 173 (23.2) 180 (19.7) 251 (19.7) 230 (15.6) <.001
NAFLD 4 (2.0) 36 (4.8) 48 (5.2) 76 (6.0) 91 (6.1) .01
HCC 5 (2.5) 47 (6.3) 75 (8.2) 155 (12.2) 291 (19.7) <.001
Total 198 746 916 1273 1476
BMI, Body Mass Index; HCC, Hepatocellular Carcinoma; LTX, liver transplantation.
F IGURE  3 Frequency of non alcoholic fatty liver disease 
(NAFLD), autoimmune liver disease, chronic viral hepatitis and  
alcoholic liver disease as indications for liver transplantation (LTX), 
shown as % of total number of LTX for each time period
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Chronic viral hepatitis NAFLD
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P = .31) and 5 years (aHR 0.80 95% CI 0.48- 1.31, P = .37) of fol-
low- up, no difference in mortality was observed. Data on mortal-
ity are presented in Table 4. Finally, overall mortality after a total 
of 26 187 person- years, showed no difference between NAFLD 
and non- NAFLD patients (aHR 1.03 95% CI 0.70- 1.53, P = .87) 
(Figure 4). Re- transplantation was performed in 3% of NAFLD pa-
tients vs 8% in other indications (P = .006). Mean graft survival 
time was 6 years in NAFLD vs 6 years in other indications (P = .63).
3.5 | Sensitivity analysis
Changing the cut- off for BMI from ≥25 kg/m2 to ≥30 kg/m2 in 
the definition of NAFLD yielded fewer cases (N = 91 vs 255). 
Using this definition, NAFLD as a transplant indication increased 
from 0.50% of total cases in the first period to 2.7% in the last 
period (P < .001). Mortality after LTX or during the waiting time 
was similar as in the main analysis, as were duration of waiting 
time and proportion of withdrawal from the waiting list (data not 
shown).
When comparing NAFLD to other liver diseases but excluding 
cases with HCC and viral hepatitis, no significant change in mortality 
estimates was found (adjusted HR for overall survival 1.03, 95% CI 
0.70- 1.53, P = .87).
4  | DISCUSSION
The results from this multinational, population- based cohort study 
from 1994 to 2015 show that NAFLD was the second most rapidly 
TABLE  3 Risk estimates during time on waiting list
Autoimmune 
liver disease
Alcoholic 
liver disease
Chronic viral 
hepatitis
Other liver 
disease NAFLD HCC
All non-  
NAFLD P- value*
Death on 
waiting list, %
3.1 7.3 5.0 3.2 3.1 1.4 4.0 .47
Withdrawal 
from waiting 
list, %
6.4 6.5 6.4 9.9 6.3 10.2 7.4 .51
Waiting time, 
days, median 
(IQR)
47 (17- 117) 31 (12- 74) 45 (17- 100) 40 (13- 113) 38 (13- 96) 29 (13- 61) 41 (15- 99) .56
Risk of death during time on waiting list, withdrawal from waiting list and waiting time. No significant differences were observed between the 6 diag-
noses groups.
*P- value for nonalcoholic fatty liver disease (NAFLD) compared to all non- NAFLD.
TABLE  4 Mortality after liver transplantation
Model 1 Model 2 Model 3
HR 95% CI P aHR 95% CI P aHR 95% CI P
90 days 1.36 0.71- 2.59 .35 1.15 0.59- 2.25 .67 2.20 0.88- 5.51 .09
1 year 1.38 0.93- 2.06 .11 1.8 0.84- 1.93 .25 1.39 0.73- 2.62 .31
5 years 0.92 0.66- 1.27 .60 0.82 0.59- 1.15 .25 0.80 0.48- 1.31 .37
Total 1.06 0.83- 1.36 .65 0.92 0.72- 1.19 .53 1.03 0.70- 1.53 .87
BMI, body mass index; CI, confidence interval; HR, hazard ratio.
Hazard ratios for overall mortality after liver transplantation for nonalcoholic fatty liver disease (NAFLD) patients compared to all other indications for 
liver transplantation. Model 1, unadjusted estimates. Model 2, adjusted for age, sex and BMI. Model 3, further adjusted for MELD.
F IGURE  4 Kaplan- Meier estimate showing post- transplant 
survival for nonalcoholic fatty liver disease (NAFLD) patients 
compared to all other liver disease (Non- NAFLD) during total time 
of follow- up
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increasing indication for LTX in the Nordic countries. This indicates 
that end- stage liver disease caused by NAFLD is a growing problem 
also in countries with lower prevalence rates of obesity than in the 
US. However, this increase has occurred from a small number of pa-
tients, and NAFLD still accounts for a small proportion of patients 
being listed for LTX in the Nordic countries.
The epidemic increase of obesity and type 2 diabetes has led to 
NAFLD being the most common chronic liver disease globally. In the 
study based on data from United Network for Organ Sharing and 
Organ Procurement and Transplantation Network registry, Wong 
et al14 demonstrated that NAFLD as a cause for liver transplantation 
increased in the US by 170% from 2003 to 2013. NAFLD was the 
diagnosis that increased most rapidly, compared to ALD, HCV and 
combined ALD/HCV. Other studies from the US have also demon-
strated a rapid increase of NAFLD patients being listed for LTX in 
relation to patients with other liver diseases.27,31,32 Obesity in the 
Nordic countries has increased during the last decades, which we 
here show is valid also for patients listed for LTX, but the prevalence 
of overweight and obesity reported from this region of the world is 
still substantially lower compared to the US.16-20 Nevertheless, the 
major results from our study are consistent with the results from 
American studies. European data on the epidemiology of NAFLD 
as an indication for LTX is lacking. From the European network of 
liver transplantation, Eurotransplant, one report describes the dis-
tribution between groups of diagnoses listed for transplantation, 
but this report does not study the temporal trends and does not 
identify NAFLD as a diagnostic group of its own.33 Therefore, our 
study brings important new knowledge to this field from a European 
perspective.
During the study period, the diagnosis with the highest rela-
tive increase was HCC. This was previously shown in a separate 
study from the NLTR, that also included cases with missing data 
on BMI.13,21 Before the establishment of generally accepted cri-
teria for LTX as a treatment, HCC as an indication for LTX was a 
subject of debate. It is therefore difficult to interpret the rapid in-
crease of HCC patients in our study when this could be attributed 
to better identification and selection of HCC cases suitable for 
LTX.34
Nonalcoholic fatty liver disease patients are at increased risk 
of surgical complications and post- surgical mortality following LTX 
owing to obesity- related risk factors.24,27,35 Patients with more co-
morbid diseases are also at a higher risk of deteriorating while on the 
waiting list and consequently, of being withdrawn from the waiting 
list. However, we found no increased risk for waiting- time mortality 
in NAFLD patients. This might be partly explained by the relatively 
high organ availability in the Nordic countries. Indeed, only 4 per 
cent of listed patients died while on the waiting list in this study. 
Moreover, we found no differences in either short- or long- term sur-
vival after LTX for NAFLD patients compared to patients with other 
liver diseases, although we did observe a trend for a higher 90- day 
mortality for NAFLD patients when adjusting for age, sex, BMI and 
MELD. Based on these results, we argue that the long- term benefit 
for NAFLD patients who are listed for LTX in the Nordic countries is 
similar to that of patients with other liver diseases. Data on the trend 
in mortality rates according to each time period has previously been 
described elsewhere.13
The major limitation of our study is the risk of misclassification 
bias when defining cases as NAFLD based on retrospective reg-
ister data. NAFLD was previously a rather unknown disease and 
has been underdiagnosed.36 Our methodology, that included all 
patients with cirrhosis of unknown cause and BMI ≥25 kg/m2, can 
be criticized for being less precise than models used in previous 
studies that mostly have used a higher cut- off for BMI at ≥30 kg/m2. 
However, when defining NAFLD using 30 kg/m2 as a cut- off, we 
found fewer NAFLD- cases but similar results in temporal trends 
as when using the BMI cut- off of 25 kg/m2. We know today that 
NAFLD can occur in patients who are modestly overweight, or 
even have a normal BMI, especially in combination with other 
traits of the metabolic syndrome or with genetic predisposition.37 
Therefore we believe the definition of NAFLD used in our study 
is correct.
Another concern about the identification of NAFLD patients 
using BMI is the influence on bodyweight from ascites. BMI was cal-
culated using data on weight at the time of listing for LTX. We found 
that more than half of LTX- patients had ascites at some point during 
the course of their disease. The NLTR do not specify whether asci-
tes was present at the specific time of listing, and therefore would 
also have impact on the accounted bodyweight, or only present at 
any time previous to listing. Presence of ascites was significantly 
less common in NAFLD compared to the other 2 groups that mainly 
includes patients with decompensated cirrhosis, ALD and chronic 
viral hepatitis. This suggests that, even though some individual pa-
tients could be misclassified as NAFLD owing to ascites causing a 
misleadingly high BMI, this is not a misclassification that affects the 
whole NAFLD group as defined in our study. On the other hand, 
some NAFLD cases might have lost bodyweight because of sarco-
penia caused by end- stage liver disease38 and could be misclassified 
as non- NAFLD. Unfortunately, no data on malnutrition or sarcopenia 
was available. The increase in BMI among LTX patients shown in our 
study is paralleled by a general increase of obesity reported from the 
Nordic countries. However, we cannot reject the possibility that the 
increase of BMI of LTX- patients over the study period is in part an 
effect of changed surgical policies allowing for more obese patients 
to be evaluated for LTX. Unfortunately, our data does not contain 
information from the 7 different LTX centres on changed guidelines 
or policies.
Also, we lack detailed information about important comorbid 
diseases, such as diabetes type 2 and other traits of the metabolic 
syndrome. With this information, the classification of NAFLD pa-
tients could have been more accurate. The limited data regarding 
primary liver diseases in the HCC group did not allow us to further 
sub- classify HCC cases. Nevertheless, we could show an increase of 
overweight and obesity in the HCC group, as expressed by increase 
in BMI. This makes it plausible that in part, the large increase in the 
number HCC patients in our study can be attributed to cases with 
NAFLD as the underlying liver disease.
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In this population- based cohort study, NAFLD as an indication for 
liver transplantation increased significantly in the Nordic countries 
between 1994 and 2015. Still, NAFLD accounts for a relatively small 
proportion of LTX indications. Mortality in NAFLD was comparable 
to other liver diseases listed for LTX. Taking into account the slow 
progress of NAFLD to cirrhosis and the increasing prevalence of 
obesity in the Nordic countries, our findings raise concerns on the 
future societal burden of NAFLD also on the outside of the US.
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